These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 38755968)

  • 21. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis.
    Fang F; Wang X; Li Z; Ni K; Xiong C
    Mol Hum Reprod; 2021 May; 27(5):. PubMed ID: 33823008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of N6-methyladenosine modulators promote breast cancer progression.
    Wu L; Wu D; Ning J; Liu W; Zhang D
    BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of N6-methyladenosine (m6A) in eye diseases.
    Gao JF; Zhang L
    Mol Biol Rep; 2021 Aug; 48(8):6145-6150. PubMed ID: 34331665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N6-methyladenosine modification participates in neoplastic immunoregulation and tumorigenesis.
    Zhao W; Li J; Ma Q; Cai J; Li A; Wu W; Lv Y; Cai M
    J Cell Physiol; 2022 Jul; 237(7):2729-2739. PubMed ID: 35342948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
    Qin S; Mao Y; Wang H; Duan Y; Zhao L
    Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.
    Zhang C; Liu J; Guo H; Hong D; Ji J; Zhang Q; Guan Q; Ren Q
    Bioengineered; 2021 Dec; 12(1):3159-3176. PubMed ID: 34187307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
    Liang Z; Kidwell RL; Deng H; Xie Q
    Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.
    Sun X; Wang H; Pu X; Wu Y; Yuan X; Wang X; Lu H
    Cancer Gene Ther; 2024 Sep; 31(9):1315-1322. PubMed ID: 38834772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer.
    Cheng Y; Wang M; Zhou J; Dong H; Wang S; Xu H
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33808751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects.
    Alam S; Giri PK
    Front Oncol; 2024; 14():1366223. PubMed ID: 38544837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N6-methyladenosine RNA modification: A promising regulator in central nervous system injury.
    Wang Q; Liang Y; Luo X; Liu Y; Zhang X; Gao L
    Exp Neurol; 2021 Nov; 345():113829. PubMed ID: 34339678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers.
    Zhu DH; Su KK; Ou-Yang XX; Zhang YH; Yu XP; Li ZH; Ahmadi-Nishaboori SS; Li LJ
    Mol Cell Biochem; 2024 Jul; 479(7):1553-1570. PubMed ID: 38856795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
    Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
    Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic modification of m
    Wang Y; Wang Y; Patel H; Chen J; Wang J; Chen ZS; Wang H
    Mol Cancer; 2023 Jun; 22(1):102. PubMed ID: 37391814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
    Cui S
    J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Liu X; Xie X; Sui C; Liu X; Song M; Luo Q; Zhan P; Feng J; Liu J
    Int J Cancer; 2024 Jun; 154(11):1877-1889. PubMed ID: 38429857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma.
    Li F; Zhang P
    Comput Math Methods Med; 2021; 2021():8715823. PubMed ID: 34840598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
    Lin H; Wang Y; Wang P; Long F; Wang T
    Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.